P3 Health Partners Inc. Annual Report - How They Did This Year

I’m breaking down P3 Health Partners’ performance over the past year. This guide translates their annual report into plain English to help you decide if this company fits your investment goals.

1. What does this company do?

P3 focuses on "value-based care." Instead of the traditional model where doctors get paid for every visit, P3 receives a set monthly fee for each patient. They use this money to manage the patient’s overall health.

They provide the "P3 Care Model," which includes data tools and administrative support for over 2,900 primary care providers. By taking on the financial risk for patient health, they are motivated to reduce hospital stays and emergency room visits. P3 doesn't own clinics; they act as the management team that improves the financial and clinical performance of independent doctor groups.

2. Financial Performance & Health

P3 is currently in a "survival and growth" phase. For the year ending December 31, 2025, they brought in $1.42 billion in revenue, a 12% increase from the previous year. Despite this growth, the company lost $215 million, largely due to the high cost of building their care management network.

A major red flag is their customer concentration. In 2025, just four health plans provided 75% of their total revenue. This is up from 59% in 2024. They are becoming very dependent on a few partners. If one of these major payers cancels a contract or lowers their fees, P3’s revenue could drop sharply.

3. Major Risks

• The "Going Concern" Warning: The company warned that there is "substantial doubt" about its ability to stay in business. As of December 31, 2025, they had only $45 million in cash. This is not enough to fund operations for the next year without raising more money or restructuring their debt.
• Debt and Rules: P3 has significant debt, including a $250 million loan. They must follow strict rules regarding their cash levels and debt. In California, regulators require them to keep specific financial reserves. If they fail to keep these reserves, they could lose their license to operate in that state.
• Stock Volatility: In April 2025, the company performed a 1-for-50 reverse stock split to keep their share price above the $1.00 minimum required by Nasdaq. This move prevented them from being delisted, but it highlights the pressure the stock has faced from ongoing losses.
• Regulatory Pressure: Their business depends on Medicare rules. If the government changes how it pays for Medicare Advantage plans, P3’s revenue could fall, even if they are operating efficiently.

4. Future Outlook

P3 hopes to lower healthcare costs by keeping seniors healthier. They are focusing on the Medicare Advantage market, which serves over 30 million people. Their strategy involves expanding into new areas using their technology. However, this is not a "set it and forget it" investment. It is a high-stakes bet on healthcare reform that requires massive spending to reach profitability.

5. The Bottom Line

As of early 2026, P3 is a high-risk, speculative company. They are burning through cash, rely heavily on a few partners, and have warned they may not be profitable soon. If you want stability, this is not the right fit. If you are looking for a "moonshot" bet on healthcare, watch their ability to secure new contracts, manage their debt, and keep their regulatory reserves in check.

Investor Checklist: Before considering an investment, look for updates on their cash position and whether they have successfully renegotiated their debt or secured new, diversified revenue streams.